VIRAMAL LIMITED
Company number 08485006 · Monitor this company
Executive summary
VIRAMAL LIMITED is a pre-revenue biotechnology company in a financially precarious but not uncommon position for its sector, with significant accumulated losses (£721,611), negative working capital (£596,993), and an explicit going concern uncertainty. While recent equity investment of approximately £398,000 has provided temporary relief and net assets remain positive at £1.36M, the company's survival depends entirely on continued external funding and the eventual commercialization of its R&D pipeline. The financial vital signs require urgent attention to cash management and funding strategy to avoid a liquidity crisis within the coming months.
Shareholders' funds
£845,062
Balance sheet as at 2025-02-28
Overview
- Company type
- Private Limited Company
- Incorporated
- 2013-04-12
- Employees
- 11 (2025 accounts · was 13 in 2024)
- Registered office
- 167-169 Great Portland Street, 5th Floor, London, England, W1W 5PF
- Postcode
- W1W 5PF
- Capital
- 567 GBP
- Accounts category
- Unaudited Abridged
Accounts
- Last made up to
- 2025-02-28
- Next due by
- 2026-11-30
- Financial year end
- 29 February
Confirmation statement
- Last statement dated
- 2026-03-02
- Next due by
- 2027-03-16
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 8 current · 7 resigned
Group structure 1 subsidiary
From persons-with-significant-control filings on the public register.
Data protection registration
Registered with the ICO as a data protection fee payer — ZB238194 (Tier 1), registered since 2021.
Information Commissioner's Office register of fee payers, licensed under the Open Government Licence.
Contact details
- Website
- viramal.com
- Phone
- +44 2074953052
Viramal is a specialist pharma company based in the UK and Sweden, at the cutting-edge of developing a portfolio of transformative biological and vaginal well-being products for women.
Previous registered addresses 2
| Address | Changed on |
|---|---|
| 22 SOUTH MOLTON STREET, LONDON, W1K 5RB | 2019-12-11 |
| C/O SIMON HOLDEN, 48-49 48-49 RUSSELL SQ, LONDON, LONDON, WC1B 4JP | 2015-03-23 |
Among its peers
Top 25%
by shareholders' funds, of 141 similar companies in W
Among the biggest employers among its local peers (11 staff).
Among the oldest 25% of its local peers, trading since 2013.
Competitors London
This company ranks 35 among research and experimental development on biotechnology in London.
The class of 2013
32%
of the 312 companies in this sector incorporated in 2013 are still active today; 63% have since been dissolved.
A fact about the year, not a forecast for this company.